ABSTRACT

Background: Despite its clinical effectiveness, allergen immunotherapy (AIT) remains controversial because serious systemic reactions can occur during its administration. Most of the studies on the safety of AIT are retrospective and use different methods, which frequently depart from daily clinical practice.

Objective: The aim of this study was to determine risk factors for adverse reactions, especially systemic adverse reactions, produced during routine AIT administration.

Methods: We registered 5,768 consecutive doses of standardized extracts administered to 273 patients in conventional schedules, following the recommendations on safety and data collection of the European Academy of Allergology and Clinical Immunology. Of the 273 patients, 236 were asthmatics, 28 had rhinitis and 9 received immunotherapy due to Hymenoptera anaphylaxis.

Results: We examined 143 local reactions (2.48% of the doses) and 145 systemic reactions (78 immediate and 67 delayed). Risk factors for developing an immediate systemic reaction were asthma severity, sensitization to molds, the most concentrated vials and a fall in peak expiratory flow of more than 15% or an immediate systemic reaction in the previous dose. Late systemic reactions were significantly more frequent with less concentrated vials and in patients with late local reactions in the previous dose. No serious reactions were registered.

Conclusions: We believe that AIT is reliable when used with strict safety protocols and administered by specialized staff. Risk factors for adverse reactions to this type of treatment can be identified and reduced by systematic data collection.


RESUMEN

Antecedentes: La inmunoterapia con alergenos es aún controvertida para algunos grupos, a pesar de su eficacia clínica, porque puede provocar reacciones sistémicas graves durante su administración. La mayoría de estudios sobre la seguridad de la inmunoterapia con alergenos son retrospectivos y emplean diferentes metodologías, muchas veces apartadas de la realidad clínica diaria.

Objetivos: El ánimo de este estudio fue conocer los factores de riesgo de las reacciones adversas, especialmente sistémicas, producidas durante la administración rutinaria de inmunoterapia.

Métodos: Registramos 5.768 dosis consecutivas de extractos estandarizados administrados a 273 pa-
cients with pautas convencionales, siguiendo las re-
comendaciones de seguridad y recogida de datos de
la EAACI (European Academy of Allergology and Cli-
nical Immunology). De todos los pacientes 236 eran
asmaicos, 28 riniticos y 9 recibieron inmunoterapia
por anafilaxia por Himenópteros.

**Results**: Registramos 143 reacciones locales
(2,48 % de las dosis), y 145 reacciones sistémicas
(78 inmediatas y 67 tardías). Encontramos como fac-
tores de riesgo para el desarrollo de reacciones in-
mediatas sistémicas: la gravedad del asma, la sensi-
bilización a hongos, los viales mas concentrados, la
caida del PEF superior al 15 % en la dosis previa y la
presencia de otra reacción sistémica inmediata en la
dosis anterior. Las reacciones sistémicas tardías fue-
ron significativamente mas frecuentes con los viales
menos concentrados y en los pacientes con reaccio-
nes locales tardías en la dosis previa. No se produjo
ninguna reacción grave.

**Conclusions**: Creemos que la IT es segura cuan-
do se emplean protocolos de seguridad estrictos y
es administrada por personal especializado. La reco-
gida sistemática de datos permite conocer y reducir
los factores de riesgo relacionados con las reaccio-
nes adversas a este tipo de tratamiento.

**Palabras clave**: Vacunas antialérgicas. Práctica clíni-
ca. Inmunoterapia. Factores de riesgo. Seguridad. Ex-
tractos estandarizados. Reacción sistémica.

**INTRODUCTION**

Allergen immunotherapy (AIT) is still a controver-
sial point for some groups, in spite of many re-
searches that guarantee its clinical effectiveness in
case of respiratory allergy due to of pollens, mites,
animal dander, animal dander (cat, dog or horse) and
in hymenoptera anaphylaxis. The consensus docu-
ments or metaanalysis locate it already in an evi-
dence-based medicine level.

However, and this is one of the arguments that can
be used against, the AIT, as any other therapeutic
form, it is not risk free and serious systemic reactions
can occur during its administration. The majority of
studies about safety with the AIT are retrospective and
they use different methods, frequently far from clin-
cal daily practice. That is the reason why we
decided to carry out a prospective study that let us
know and reduce risk factors concerning adverse re-
actions, especially systemic, produced during the rou-
tine procedure of AIT administration in our Im-
munotherapy Unit. In this unit we work with a very
well trained nursery staff (more than 3000 doses ad-
ministered per year), we use only standardized ex-
tracts and we dispose of an appropriate training or al-
lergists, immunotherapy clinic support staff and a
computerized data recollection, as well as necessary
material to treat an eventual anaphylactic reaction,
according to the European Academy of Allergology
and Clinical Immunology (EAACII) recommendations.

**METHODS**

**Patients**

We evaluated 273 consecutive patients between 4
and 65 years of age, both included an average of
23.42 ± 15.79 years old, with indication of im-
munotherapy: 264 for respiratory pathology and 9 for
hymenoptera anaphylaxis. 28 of the patients (10 %
of the sum) with respiratory allergy exclusively
showed rhinoconjunctivitis and the rest were asth-
matic (85.2 %), 33.3 % of these with intermittent
asthma, 43.7 % with persistent mild asthma and
22.9 % with persistent moderate asthma according to
NHBLI/WHO consensus. Patients maintain the nec-
essary symptomatic treatment for their clinical sta-
bility during the course of the IT. The following pa-
tients’ variables were analysed: age, sex, diagnostic
and severity in asthmatic, sensitizing allergens,
PDD20 methacholine and environmental conditions
(origin of the population, presence of pets at home,
kind of house and level of antigen exposition).

**Immunotherapy**

The vaccines used were all standardized in accor-
dance to the International Consensus and follow-
ing conventional schedules. In every patient we tried
to reach the maximum dose recommended by differ-
et manufacturers. The vaccines with modified ex-
tracts or allergoids were administered in a presea-
sonal regimen (from September to March), being all
the rest administered following a continuous sched-
ule. Of the total of administered vaccines 74.4 %
were of pollens, 7.8 % of mites, 11 % of moulds (Al-
ternaria alternata), 3.8 % animal dander (cat, dog or
horse) and 3.2 % hymenoptera venom (Vespula or
Polistes).

**Doses – Safety monitoring**

Every dose was administered in our AIT unit fol-
lowing the recommendations of the AIT committee of
the Sociedad Española de Alergología e Inmunología Clínica and the AIT subcommittee of the EAACI supervised by an allergologist. All data concerning each dose and the incidences were registered, always including the date-time, administered dose, PEF predose and 30 minutes later, symptoms 30 minutes later and local or systemic reactions in the previous dose, by the administrator nurse in a computing database. Patients were asked before each dose about any reason that could indicate a modification in the schedule, including the illness activity, changes in medical treatment or appearance of a concomitant disease. We consider immediate local reactions those bigger than 5 centimetres in the initial minutes, and late systemic reactions those bigger than 10 centime-
tres. The gradations of immediate local and late reactions and the modification of the therapeutic regimen followed the EAACI recommendations.

Statistic

The collected data were processed in a data base (Access® data base Microsoft®), SPSS (Superior Performing Software Systems 10.0) was used for statistical analysis. Comparative analysis of groups was carried out by the chi-square nonparametric test and the exact Fisher’s test. For the multivariable research we followed every step of the logistic method. A P value of < 0.05 was considered statistically significant.

RESULTS

A total of 5,768 administered doses to 273 patients (122 men and 151 women) were analysed. 27.07 % (75 patients) were younger than 10 years old and they received 1469 doses. 3371 doses belong to the build-up phase and 2,397 to the maintenance therapy (table I). 177 were aqueous extracts (hymenoptera venom), 3,973 adsorbed vaccines in aluminium hydroxide, and 1,618 allergoids. All patients but 9 (5 due to local reactions and 4 to systemic reactions) reached the maximum preestablished dose. The number and type of registered adverse reactions are exposed in table II. Only 1 patient presented both types of systemic reaction (immediate and late) after different doses of an Alternaria alternata extract. Most of the immediate systemic reaction (ISR) occurred significantly with the most concentrated vial, in more severe asthmatic patients, in those sensitized to moulds and in children (< 10as). Otherwise, we found that an asymptomatic decrease of more than 15 % in PEF 30 minutes after a dose, showed a significative higher risk of suffering an ISR in the following dose (table III). Also, the presence of an ISR in a previous dose highly increased the probability of being repeated. Polisensitized patients (to more than 3 antigens) showed a higher probability of developing an ISR (p < 0.05) (fig. 1). As an interesting fact we found, according to age, that children younger than 10 years old sensitized to animal dander or with a > 15 % fall in PEF in the previous dose, highly increased the risk of ISR.

In relation to the late systemic reactions (LSR), the higher risk was related to the least concentrated vials (increasing dose regimen), and to the presence of another LSR (p = 0.07) or a late local reaction (LLR) in the previous dose.

### Table I

<table>
<thead>
<tr>
<th>Composition</th>
<th>Increase</th>
<th>Maintenance</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pollens (gramineae and/or trees, no cupressaceae)</td>
<td>1,761</td>
<td>705</td>
<td>2,466</td>
<td>43.1</td>
</tr>
<tr>
<td>Pollens (with cupressaceae)</td>
<td>174</td>
<td>378</td>
<td>552</td>
<td>9.57</td>
</tr>
<tr>
<td>Pollens (with weeds)</td>
<td>381</td>
<td>437</td>
<td>818</td>
<td>14.18</td>
</tr>
<tr>
<td>Mites (D. pteronissinus and/or D. farinae)</td>
<td>234</td>
<td>366</td>
<td>600</td>
<td>10.4</td>
</tr>
<tr>
<td>Moulds (alternaria alternata)</td>
<td>476</td>
<td>345</td>
<td>821</td>
<td>14.23</td>
</tr>
<tr>
<td>Epithelia (cats, dogs or horse)</td>
<td>227</td>
<td>87</td>
<td>314</td>
<td>5.44</td>
</tr>
<tr>
<td>Hymenoptera (vespula and/or polistes)</td>
<td>98</td>
<td>79</td>
<td>177</td>
<td>3.07</td>
</tr>
<tr>
<td>Total</td>
<td>3,371</td>
<td>2,397</td>
<td>5,768</td>
<td>100.0</td>
</tr>
</tbody>
</table>

### Table II

<table>
<thead>
<tr>
<th>N° doses (%)</th>
<th>N° patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate local reactions</td>
<td>60 (1.0)</td>
</tr>
<tr>
<td>Late local reactions</td>
<td>85 (1.4)</td>
</tr>
<tr>
<td>Immediate systemic reactions</td>
<td>78 (1,3)</td>
</tr>
<tr>
<td>Grade 2 (mid rhinitis or asthma)</td>
<td>70</td>
</tr>
<tr>
<td>Grade 3 (urtica, angioedema or mod-sev. asthma)</td>
<td>8</td>
</tr>
<tr>
<td>Late systemic reactions</td>
<td>67 (1,1)</td>
</tr>
<tr>
<td>Urtica</td>
<td>6</td>
</tr>
<tr>
<td>Angioedema</td>
<td>4</td>
</tr>
<tr>
<td>Eczema</td>
<td>2</td>
</tr>
<tr>
<td>Rhinoconjunctivitis</td>
<td>19</td>
</tr>
<tr>
<td>Asthma</td>
<td>37</td>
</tr>
</tbody>
</table>
DISCUSSION

In some researches that employ similar doses regimen and method to ours the RS incidence is smaller than the one we found (2.53 % of the doses)\(^26-28\). This fact could be due to, among other factors, that our series include many mould vaccines that have demonstrated, especially in children, to be worse tolerated\(^29,30\). On the other hand it is possible that asthma severity in our asthmatic patients was as a whole greater than in another studies. The use of maximum doses with some extracts in which the optimum doses adapted to the patient are not defined could also collaborate to the increase of SR\(^15\). However the percentage of patients (36.6 %) who show some SR agrees with Abramson et al review\(^31\).

Neither the ISR treated by us nor the LSR showed by our patients were serious, responding all of them to conventional treatment so that we consider that the AIT was safe in our patients.

The risk factors to suffer from RS found in our population, as asthma severity or patients’ polisensitization grade, are in agreement with those found by other authors\(^29\). The population that we attend comes from a residential area nearby Madrid, with a continental climate that stands out two pollination sharp points (February for cupressaceae and May-June for grass and olive tree pollen), as well as a great proportion of one family-houses and the presence of pets in 50 % of these residences. This could explain that the collective that suffers more from systemic reactions have been housekeepers, exposed more often to house dust mites, moulds and animal dander. This collective is frequently immigrant population that fulfil the treatments worse, and, particularly for asthma, this is usually worse controlled.

We have found that a decrease of more than 15 % in PEF after a dose is a risk factor to present an ISR in the following dose. This fact supports the PEF monitoring recommendations of the EAACI and it can be of great profit in children and other patients, that don’t express their symptoms properly, which preclude possible modifications in the dose schedule that would not work otherwise.

As well as in previous studies the local reactions didn’t predict the ISR, but they predicted the LSR, what allows us to warn patients about it. In that sense the use of premedication, that we don’t employ, but that some other authors do\(^32\), could hide the warning that suppose to present a LLR, although further researches are needed to clear up this aspect.

According to our safety medical records we don’t consider the administration mistakes as a risk factor (RF). We also minimize the possibility of suffering severe systemic reactions contraindicating the AIT administration in patients using betablocking, with severe asthma or very unstable, or with another medical condition that could reduce the survival in case of a systemic reaction.

We don’t find as a RF the administration dates because of the high number of doses administered during the pollinic season. It is possible that clinical stabilization of patients could reduce the risk of reactions throughout these times.

In our patients, in agreement with another researches\(^27,33\) the most concentrated vials provoked more ISR, which we treated immediately in our unit. The least concentrated vials provoked more LSR that usually the patient suffered at home. Dose-

---

**Table III**

<table>
<thead>
<tr>
<th>Risk factors of systemic reactions</th>
<th>RR (Relative risk)</th>
<th>IC (95 % RR)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate systemic reactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt; 10 years</td>
<td>2.3</td>
<td>1.2-4.6</td>
<td>0.01</td>
</tr>
<tr>
<td>Sensitization to moulds</td>
<td>4.3</td>
<td>2.6-7.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Persistent moderate asthma</td>
<td>2.0</td>
<td>1.3-3.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Most concentrated vials</td>
<td>2.1</td>
<td>1.1-3.8</td>
<td>0.016</td>
</tr>
<tr>
<td>Previous PEF &gt; 15 % fall</td>
<td>3.2</td>
<td>1.4-7.6</td>
<td>0.007</td>
</tr>
<tr>
<td>SR in previous doses</td>
<td>5.4</td>
<td>2.4-12.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Late systemic reactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous late local reaction</td>
<td>4.1</td>
<td>1.2-13.5</td>
<td>0.019</td>
</tr>
<tr>
<td>Less concentrated vials</td>
<td>2.4</td>
<td>1.6-4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Figure 1**—Percentage of patients that show immediate systemic reactions in accordance with the number of allergenic sources to whom they are sensitized: Pollens (gramineae and/or trees, no Cupressaceae), Cupressaceae, Weeds, Mites, Moulds, Epithelia or Hymenoptera.
schedules that reject first doses could reduce the LSR incidence without increasing the ISR, though further investigations are needed to assure this possibility. We agree with Tabar et al with the idea that the way of obtaining information in this research must be a priori objective in any Allergy Unit, in order to reduce the incidence of adverse reactions with AIT and to better inform patients. We also agree with the idea that the AIT administration by specialized staff with strict medical records (we don't register neither severe reaction nor anaphylactic shock) is safe enough to exclude any patient in which it is indicated.

We have found as unavoidable RF: sensitisation to moulds or age (children); but other factors such as the PEF variation, ISR or LRR in previous doses that could allow modifying the dosage regimen and reducing adverse reactions; and in every case to inform our patients.

ACKNOWLEDGMENTS

We thank the nurses of our allergy service: Isabel Delgado, Angela Alvarez, Dioniás Alvarez, Inmaculada Llanos and Kati Rengifo for their help in this study and everyday.

REFERENCES